Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 635702-60-2 ] Purity: 97% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support Online Technical Q&A

Product Details of [ 635702-60-2 ]

CAS No. :	635702-60-2
Formula :	C₉H₁₂ClN₃
M.W :	197.67
SMILES Code :	Cl.CN1N=C2C=C(N)C=CC2=C1C
MDL No. :	MFCD09258896
InChI Key :	DYTQJZDNKWQSLS-UHFFFAOYSA-N
Pubchem ID :	46864001

Safety of [ 635702-60-2 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Calculated chemistry of [ 635702-60-2 ] Show Less

Physicochemical Properties

Num. heavy atoms	13
Num. arom. heavy atoms	9
Fraction Csp3	0.22
Num. rotatable bonds	0
Num. H-bond acceptors	1.0
Num. H-bond donors	1.0
Molar Refractivity	57.33
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	43.84 ?2

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	0.0
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	2.09
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	2.27
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	1.46
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	1.15
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	1.4

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-2.89
Solubility	0.252 mg/ml ; 0.00127 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-2.64
Solubility	0.452 mg/ml ; 0.00229 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-2.49
Solubility	0.64 mg/ml ; 0.00324 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	Yes
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.02 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	1.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	1.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.61

Application In Synthesis of [ 635702-60-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 635702-60-2 ]
Downstream synthetic route of [ 635702-60-2 ]

[ 635702-60-2 ] Synthesis Path-Upstream 1~3

1
[ 444731-73-1 ]
[ 635702-60-2 ]

Yield	Reaction Conditions	Operation in experiment
96%	With hydrogenchloride; tin(ll) chloride In diethylene glycol dimethyl ether; water at 0℃; for 0.583333 h;	To a stirred solution of 2, [3-DIMETHYL-6-NITRO-2H-INDAZOLE] (1.13 g) in 2- methoxyethyl ether (12 [ML),] at [0] [C,] was added a solution of 4.48 g of tin [(LL)] chloride in 8.9 ml of concentrated HCI dropwise over 5 min. After the addition was complete, the ice bath was removed and the solution was allowed to stir for an additional 30 min. Approximately 40 ml of diethyl ether was added to reaction, resulting in precipitate formation. The resulting precipitate was isolated by filtration and washed with diethyl ether, and afforded a yellow solid (1.1 g, 95 [percent),] the HCI salt 2,3- [DIMETHYL-2H-INDAZOL-6-AMINE.APOS;H] NMR (300 MHz, [DMSO-D6)] 8 7. [77] (d, [J =] 8.9 [HZ,] [1 H),] 7.18 (s, [1 H),] 7.88 (m, [1 H),] 4.04 (s, 3H), 2.61 (s, 3H). MS [(ES+,] m/z) 162 (M+H).
95%	With hydrogenchloride; tin(ll) chloride In diethylene glycol dimethyl ether; water at 0℃; for 0.583333 h;	To a stirred solution of 2,3-dimethyl-6-nitro-2H-indazole (1.13 g) in 2- methoxyethyl ether (12 ml), at 0 ⁹C, was added a solution of 4.48 g of tin(ll) chloride in 8.9 ml of concentrated HCI dropwise over 5 min. After the addition was complete, the ice bath was removed and the solution was allowed to stir for an additional 30 min. Approximately 40 ml of diethyl ether was added to reaction, resulting in precipitate formation. The resulting precipitate was isolated by filtration and washed with diethyl ether, and afforded a yellow solid (1.1 g, 95 percent), the HCI salt 2,3-dimethyl-2H-indazol- 6-amine. ¹H NMR (300 MHz, DMSO-d₆) δ 7.77 (d, J = 8.9 Hz, 1 H), 7.18 (s, 1H), 7.88 (m, 1 H), 4.04 (s, 3H), 2.61 (s, 3H). MS (ES+, m/z) 162 (M+H).
95%	With tin(ll) chloride In diethylene glycol dimethyl ether; water at 0℃; for 0.583333 h;	To a stirred solution of 2,3-dimethyl-6-nitro-2H-indazole (1.13 g) in 2- methoxyethyl ether (12 ml), at 0 9C, was added a solution of 4.48 g of tin(ll) chloride in 8.9 ml of concentrated HCI dropwise over 5 min. After the addition was complete, the ice bath was removed and the solution was allowed to stir for an additional 30 min. Approximately 40 ml of diethyl ether was added to reaction, resulting in precipitate formation. The resulting precipitate was isolated by filtration and washed with diethyl ether, and afforded a yellow solid (1.1 g, 95 percent), the HCI salt 2,3-dimethyl-2H-indazol- 6-amine. 1H NMR (300 MHz, DMSO-d6) δ 7.77 (d, J = 8.9 Hz, 1 H), 7.18 (s, 1 H), 7.88 (m, 1 H), 4.04 (s, 3H), 2.61 (s, 3H). MS (ES+, m/z) 162 (M+H).

References: [1] Patent: WO2003/106416, 2003, A2, . Location in patent: Page 42-43.
[2] Patent: WO2007/64753, 2007, A2, . Location in patent: Page/Page column 27.
[3] Journal of Medicinal Chemistry, 2008, vol. 51, # 15, p. 4632 - 4640.
[4] Patent: WO2006/20564, 2006, A1, . Location in patent: Page/Page column 14.

2
[ 6494-19-5 ]
[ 635702-60-2 ]

References: [1] Patent: US2008/293691, 2008, A1, .
[2] Patent: US2008/293691, 2008, A1, .
[3] Patent: WO2005/105094, 2005, A2, .
[4] Patent: WO2007/143483, 2007, A2, .
[5] Patent: US2008/293691, 2008, A1, .
[6] Patent: WO2005/105094, 2005, A2, .
[7] Patent: WO2007/143483, 2007, A2, .
[8] Patent: WO2005/105094, 2005, A2, .

3
[ 635702-59-9 ]
[ 635702-60-2 ]

References: [1] Patent: US2008/293691, 2008, A1, .
[2] Patent: WO2005/105094, 2005, A2, .
[3] Patent: WO2007/143483, 2007, A2, .

[ 635702-60-2 ] Synthesis Path-Downstream 1~12

1
[ 444731-73-1 ]
[ 635702-60-2 ]

Yield	Reaction Conditions	Operation in experiment
96%	With hydrogenchloride; tin(ll) chloride; In diethylene glycol dimethyl ether; water; at 0℃; for 0.583333h;	To a stirred solution of 2, [3-DIMETHYL-6-NITRO-2H-INDAZOLE] (1.13 g) in 2- methoxyethyl ether (12 [ML),] at [0] [C,] was added a solution of 4.48 g of tin [(LL)] chloride in 8.9 ml of concentrated HCI dropwise over 5 min. After the addition was complete, the ice bath was removed and the solution was allowed to stir for an additional 30 min. Approximately 40 ml of diethyl ether was added to reaction, resulting in precipitate formation. The resulting precipitate was isolated by filtration and washed with diethyl ether, and afforded a yellow solid (1.1 g, 95 [%),] the HCI salt 2,3- [DIMETHYL-2H-INDAZOL-6-AMINE.'H] NMR (300 MHz, [DMSO-D6)] 8 7. [77] (d, [J =] 8.9 [HZ,] [1 H),] 7.18 (s, [1 H),] 7.88 (m, [1 H),] 4.04 (s, 3H), 2.61 (s, 3H). MS [(ES+,] m/z) 162 (M+H).
95%	With hydrogenchloride; tin(ll) chloride; In diethylene glycol dimethyl ether; water; at 0℃; for 0.583333h;	To a stirred solution of 2,3-dimethyl-6-nitro-2H-indazole (1.13 g) in 2- methoxyethyl ether (12 ml), at 0 9C, was added a solution of 4.48 g of tin(ll) chloride in 8.9 ml of concentrated HCI dropwise over 5 min. After the addition was complete, the ice bath was removed and the solution was allowed to stir for an additional 30 min. Approximately 40 ml of diethyl ether was added to reaction, resulting in precipitate formation. The resulting precipitate was isolated by filtration and washed with diethyl ether, and afforded a yellow solid (1.1 g, 95 %), the HCI salt 2,3-dimethyl-2H-indazol- 6-amine. 1H NMR (300 MHz, DMSO-d6) delta 7.77 (d, J = 8.9 Hz, 1 H), 7.18 (s, 1H), 7.88 (m, 1 H), 4.04 (s, 3H), 2.61 (s, 3H). MS (ES+, m/z) 162 (M+H).
95%	With tin(ll) chloride;hydrogenchloride; In diethylene glycol dimethyl ether; water; at 0℃; for 0.583333h;	To a stirred solution of 2,3-dimethyl-6-nitro-2H-indazole (1.13 g) in 2- methoxyethyl ether (12 ml), at 0 9C, was added a solution of 4.48 g of tin(ll) chloride in 8.9 ml of concentrated HCI dropwise over 5 min. After the addition was complete, the ice bath was removed and the solution was allowed to stir for an additional 30 min. Approximately 40 ml of diethyl ether was added to reaction, resulting in precipitate formation. The resulting precipitate was isolated by filtration and washed with diethyl ether, and afforded a yellow solid (1.1 g, 95 %), the HCI salt 2,3-dimethyl-2H-indazol- 6-amine. 1H NMR (300 MHz, DMSO-d6) delta 7.77 (d, J = 8.9 Hz, 1 H), 7.18 (s, 1 H), 7.88 (m, 1 H), 4.04 (s, 3H), 2.61 (s, 3H). MS (ES+, m/z) 162 (M+H).

95%	With hydrogenchloride; tin(ll) chloride; In diethylene glycol dimethyl ether; water; at 0℃; for 0.583333h;Inert atmosphere; Cooling with ice;	Intermediate Example 11 Preparation of 2,3-dimethyl-2H-indazol-6-amine To a stirred solution of 18.5 g (0.11 mol) of 3-methyl-6-nitro-1H-indazole in 350 ml acetone, at room temperature, was added 20 g (0.14 mol) of trimethyloxonium tetraflouroborate. After the solution was allowed to stir under argon for 3 hours, the solvent was removed under reduced pressure. To the resulting solid was added saturated aqueous NaHCO3 (600 ml) and a 4:1 mixture of chloroform-isopropanol (200 ml), and the mixture was agitated and the layers were separated. The aqueous phase was washed with additional chloroform: isopropanol (4 x 200 ml) and the combined organic phase was dried (Na2SO4). Filtration and removal of solvent gave a tan solid. The solid was washed with ether (200 ml) to afford 2,3-dimethyl-6-nitro-2H-indazole as a yellow solid (15.85 g, 73 %). 1H NMR (300 MHz, d6DMSO) delta 8.51 (s, 1H), 7.94 (d, J = 9.1 Hz, 1H), 7.73 (d, J = 8.9 Hz, 1H), 4.14 (s, 3H), 2.67 (s, 3H). MS (ES+, m/z) 192 (M+H).; To a stirred solution of 2,3-dimethyl-6-nitro-2H-indazole (1.13 g) in 2-methoxyethyl ether (12 ml), at 0 C, was added a solution of 4.48 g of tin(II) chloride in 8.9 ml of concentrated HCl dropwise over 5 min. After the addition was complete, the ice bath was removed and the solution was allowed to stir for an additional 30 min. Approximately 40 ml of diethyl ether was added to reaction, resulting in precipitate formation. The resulting precipitate was isolated by filtration and washed with diethyl ether, and afforded a yellow solid (1.1 g, 95 %), the HCl salt 2,3-dimethyl-2H-indazol-6-amine. 1H NMR (300 MHz, d6DMSO) delta 7.77 (d, J = 8.9 Hz, 1H), 7.18 (s, 1H), 7.88 (m, 1H), 4.04 (s, 3H), 2.61 (s, 3H). MS (ES+, m/z) 162 (M+H).
95%	With hydrogenchloride; tin(ll) chloride; In diethylene glycol dimethyl ether; water; at 0℃; for 0.583333h;	Intermediate Example 2 Preparation of 2,3-dimethyl-6-amino-2H-indazole Procedure 1: To a stirred solution of 2,3-dimethyl-6-nitro-2H-indazole (1.13 g) in 2-methoxyethyl ether (12 ml), at 0 C., was added a solution of 4.48 g of tin(II) chloride in 8.9 ml of concentrated HCl dropwise over 5 min. After the addition was complete, the ice bath was removed and the solution was allowed to stir for an additional 30 min. Approximately 40 ml of diethyl ether was added to reaction, resulting in precipitate formation. The resulting precipitate was isolated by filtration and washed with diethyl ether, and afforded a yellow solid (1.1 g, 95%), the HCl salt 2,3-dimethyl-2H-indazol-6-amine. 1H NMR (300 MHz, DMSO-d6) delta 7.77 (d, J=8.9 Hz, 1H), 7.18 (s, 1H), 7.88 (m, 1H), 4.04 (s, 3H), 2.61 (s, 3H). MS (ES+, m/z) 162 (M+H).
95%	With hydrogenchloride; tin(ll) chloride; In diethylene glycol dimethyl ether; water; at 0℃; for 0.583333h;	Intermediate Example 2 Preparation of 2,3-dimethyl-6-amino-2H-indazole Procedure 1: To a stirred solution of 2,3-dimethyl-6-nitro-2H-indazole (1.13 g) in 2- methoxyethyl ether (12 ml), at 0 C, was added a solution of 4.48 g of tin(II) chloride in 8.9 ml of concentrated HCI dropwise over 5 min. After the addition was complete, the ice bath was removed and the solution was allowed to stir for an additional 30 min. Approximately 40 ml of diethyl ether was added to reaction, resulting in precipitate formation. The resulting precipitate was isolated by filtration and washed with diethyl ether, and afforded a yellow solid (1.1 g, 95 %), the HCI salt 2,3-dimethyl-2H-indazol-6-amine.
95%	With hydrogenchloride; tin(ll) chloride; In diethylene glycol dimethyl ether; water; at 0℃; for 0.583333h;	To a stirred solution of 2,3-dimethyl-6-nitro-2/-/-indazole (1.13 g) in 2- methoxyethyl ether (12 ml), at 0 0C, was added a solution of 4.48 g of tin(ll) chloride in 8.9 ml of concentrated HCI dropwise over 5 min. After the addition was complete, the ice bath was removed and the solution was allowed to stir for an additional 30 min. Approximately 40 ml of diethyl ether was added to reaction, resulting in precipitate formation. The resulting precipitate was isolated by filtration and washed with diethyl ether, and afforded a yellow solid (1.1 g, 95 %), the HCI salt 2,3-dimethyl-2H-indazol-6- amine. 1H NMR (300 MHz, DMSOd6) delta 7.77 (d, J = 8.9 Hz, 1 H), 7.18 (s, 1 H), 7.88 (m, 1 H), 4.04 (s, 3H), 2.61 (s, 3H). MS (ES+, m/z) 162 (M+H).
95%	With hydrogenchloride; tin(ll) chloride; In ethanol; water; at 0℃;	After stirring and mixing a concentrated hydrochloric acid solution (80 mL) of stannous chloride (0.24 mol) at 0 C. with ethanol (150 mL)From Li E 10 into the third mixing valve 11, the flow rate of Li E 10 was 2.56 mL / min. At the same time, the second micro-reaction in step (2)The effluent 2,3-dimethyl-6-nitro-2H-indazole product (0.0216 mol) from the reactor 9 flows into the third mixing valve 11. Two stocksAfter fully mixed, it enters the third micro-reactor 12 in the second continuous micro-channel reaction device, reacts at room temperature, and the residence timeFor 7.6min, the second receiving device 13 collects the reaction effluent, the second receiving device 13 is a container for ethanol, the volume of ethanol1.5L, 2,3-dimethyl-2H-indazole-6-amine hydrochloride was precipitated, S was the product, and the yield was 95%.

References: [1]Patent: WO2003/106416,2003,A2 .Location in patent: Page 42-43.
[2]Patent: WO2007/64753,2007,A2 .Location in patent: Page/Page column 27.
[3]Journal of Medicinal Chemistry,2008,vol. 51,p. 4632 - 4640.
[4]Patent: WO2006/20564,2006,A1 .Location in patent: Page/Page column 14.
[5]Patent: EP2311825,2015,B1 .Location in patent: Paragraph 0178 - 0180.
[6]Patent: US2008/293691,2008,A1 .Location in patent: Page/Page column 8-9.
[7]Patent: WO2005/105094,2005,A2 .Location in patent: Page/Page column 29-30.
[8]Patent: WO2007/143483,2007,A2 .Location in patent: Page/Page column 30.
[9]Patent: CN108299304,2018,A .Location in patent: Paragraph 0029; 0034-0035; 0039; 0040; 0044-0045; 0049.

2
[ 3934-20-1 ]
[ 635702-60-2 ]
[ 444731-74-2 ]

Yield	Reaction Conditions	Operation in experiment
89%	With sodium hydrogencarbonate; In tetrahydrofuran; ethanol; at 20 - 85℃; for 4.0h;Inert atmosphere;	Intermediate Example 12 Preparation of N-(2-chloropyrimidin-4-yl)-2,3-dimethyl-2H-indazol-6-amine To a stirred solution of Intermediate Example 11 (2.97 g, .015 mol) and NaHCO3 (5.05 g, .06 mol) in THF (15 mL) and ethanol (60 mL) was added 2,4-dichloropyrimidine (6.70 g, .045 mol) at room temperature. After the reaction was stirred for four hours at 85 C, the suspension was cooled to rt., filtered and washed thoroughly with ethyl acetate. The filtrate was concentrated under reduced pressure, and the resulting solid was triturated with ethyl acetate to yield 3.84 g (89 % yield) of N-(2-chloropyrimidin-4-yl)-2,3-dimethyl-2H-indazol-6-amine. 1H NMR (400 MHz, d6DMSO) delta 7.28 (d, J = 9.0 Hz, 1H), 6.42 (d, J = 8.8 Hz, 1H), 6.37 (s, 1H), 5.18 (br s, 1H), 3.84 (s, 3H), 2.43 (s, 3H). MS (ES+, m/z) 274 (M+H).

References: [1]Journal of Medicinal Chemistry,2008,vol. 51,p. 4632 - 4640.
[2]Patent: EP2311825,2015,B1 .Location in patent: Paragraph 0181; 0182.

3
[ 6494-19-5 ]
[ 635702-60-2 ]

References: [1]Patent: US2008/293691,2008,A1 .
[2]Patent: US2008/293691,2008,A1 .
[3]Patent: US2008/293691,2008,A1 .
[4]Patent: WO2005/105094,2005,A2 .
[5]Patent: WO2007/143483,2007,A2 .

4
[ 635702-59-9 ]
[ 635702-60-2 ]

References: [1]Patent: US2008/293691,2008,A1 .
[2]Patent: WO2005/105094,2005,A2 .
[3]Patent: WO2007/143483,2007,A2 .

5
[ 444731-74-2 ]
[ 635702-60-2 ]
[ 1226499-98-4 ]